Goldman Sachs’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.87M | Buy |
1,143,536
+740,936
| +184% | +$5.1M | ﹤0.01% | 2446 |
|
|
2025
Q1 | $1.16M | Sell |
402,600
-139,658
| -26% | -$402K | ﹤0.01% | 3709 |
|
|
2024
Q4 | $2.55M | Sell |
542,258
-385,703
| -42% | -$1.81M | ﹤0.01% | 3321 |
|
|
2024
Q3 | $3.31M | Buy |
927,961
+367,469
| +66% | +$1.31M | ﹤0.01% | 3029 |
|
|
2024
Q2 | $3.48M | Sell |
560,492
-249,778
| -31% | -$1.55M | ﹤0.01% | 2868 |
|
|
2024
Q1 | $7.65M | Sell |
810,270
-61,233
| -7% | -$578K | ﹤0.01% | 2268 |
|
|
2023
Q4 | $5.88M | Buy |
871,503
+612,276
| +236% | +$4.13M | ﹤0.01% | 2479 |
|
|
2023
Q3 | $1.15M | Sell |
259,227
-128,505
| -33% | -$571K | ﹤0.01% | 3449 |
|
|
2023
Q2 | $1.28M | Buy |
387,732
+89,921
| +30% | +$297K | ﹤0.01% | 3469 |
|
|
2023
Q1 | $849K | Sell |
297,811
-17,617
| -6% | -$50.2K | ﹤0.01% | 3768 |
|
|
2022
Q4 | $2.3M | Sell |
315,428
-29,302
| -8% | -$213K | ﹤0.01% | 3192 |
|
|
2022
Q3 | $2.79M | Buy |
344,730
+60,425
| +21% | +$489K | ﹤0.01% | 3101 |
|
|
2022
Q2 | $1.39M | Buy |
284,305
+46,663
| +20% | +$229K | ﹤0.01% | 3720 |
|
|
2022
Q1 | $5.62M | Buy |
237,642
+152,759
| +180% | +$3.61M | ﹤0.01% | 2706 |
|
|
2021
Q4 | $1.5M | Buy |
84,883
+22,381
| +36% | +$396K | ﹤0.01% | 3710 |
|
|
2021
Q3 | $1.76M | Buy |
62,502
+35,036
| +128% | +$988K | ﹤0.01% | 3580 |
|
|
2021
Q2 | $288K | Buy |
27,466
+13,099
| +91% | +$137K | ﹤0.01% | 4725 |
|
|
2021
Q1 | $169K | Sell |
14,367
-490
| -3% | -$5.76K | ﹤0.01% | 4892 |
|
|
2020
Q4 | $174K | Buy |
+14,857
| New | +$174K | ﹤0.01% | 4314 |
|
|
2019
Q4 | – | Sell |
-27,871
| Closed | -$185K | – | 4318 |
|
|
2019
Q3 | $185K | Buy |
+27,871
| New | +$185K | ﹤0.01% | 3933 |
|